We used this model to evaluate the in vivo effects of Klf9 KO on obesity/adiposity and related parameters including hepatic lipid content, circulating adipokine concentrations, and hepatic and systemic oxidative stress, all of which are considered to positively influence HCC risk. Here, KLF9 is linked to obesity disorder.